Over-Optimistic Portrayal of Life-Supporting Treatments in Newspapers and Internet
By Thaddeus Pope,
Medical Futility Blog
| 08. 09. 2014
Several Taiwanese researchers have
just published a new study: "Over-Optimistic Portrayal of Life-Supporting Treatments in Newspapers and on the Internet: A Cross-Sectional Study Using Extra-Corporeal Membrane Oxygenation as an Example."
From the article's conclusion: Newspapers and the Internet have the potential to influence patients' knowledge and attitudes toward medical decision-making by providing over-optimistic medical information through the following ways:
- First, the mass media tend to attract the public’s attention by reporting the positive outcome of an important breakthrough in clinical medicine
- Second, the mass media tend to report patients who survive to hospital discharge, rather than those who die during hospital stay
- Third, the survived patients and their stories are more likely to be duplicated in newspapers and on Internet web pages than those who die during hospital stay.
Newspaper readers and Internet users may, therefore, mistakenly believe that ECMO can usually rescue patients from all life-threatening conditions. However, ECMO, similar to other aggressive LST such as CPR, is ethically appropriate to be initiated on patients with
reversible diseases, not on those with irreversible diseases.
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...